Dr. Bhavna G, G18035, Dr. Pramod Kumar Sharma, Dr. Jagdish Prasad Rout
Purpose: to study the effectiveness of intravitreal Ranibizumab injection(IRVI) in chronic CSR.
Methods: patients with symptomatic CSR of >3months were prospectively recruited. Patients were randomly assigned to IVRI(0.5mg/0.05ml) or observation & followed for 6months. Snellen’s BCVA & central foveal thickness(CFT) were assessed at baseline & at regular follow-ups.
Results:all patients had increased BCVA, decreased CFT & reduction of neurosensory detachment. However, this required more time in the observation group. Changes in mean BCVA & mean CFT were not significantly different between the groups at 6months.
Conclusion:IVRI for chronic CSR hastens reduction of neurosensory detachment compared to observation alone. At 6months, BCVA & CFT did not differ between the 2 groups.